CL2012000493A1 - Procedimiento de preparacion de 2-alquilamino-3-piridin-n-bencilpiperazin cetonas. - Google Patents

Procedimiento de preparacion de 2-alquilamino-3-piridin-n-bencilpiperazin cetonas.

Info

Publication number
CL2012000493A1
CL2012000493A1 CL2012000493A CL2012000493A CL2012000493A1 CL 2012000493 A1 CL2012000493 A1 CL 2012000493A1 CL 2012000493 A CL2012000493 A CL 2012000493A CL 2012000493 A CL2012000493 A CL 2012000493A CL 2012000493 A1 CL2012000493 A1 CL 2012000493A1
Authority
CL
Chile
Prior art keywords
benzylpiperazine
alkylamino
ketones
pyridine
procedure
Prior art date
Application number
CL2012000493A
Other languages
English (en)
Inventor
Sripathy Venkatraman
Syed Mahmood
Bingidimi I Mobele
Olga Lapina
Kellie Vercoe
Ying Li
Jonathan Salsbury
M Mclaws
Original Assignee
Neuralstem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000493(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuralstem Inc filed Critical Neuralstem Inc
Publication of CL2012000493A1 publication Critical patent/CL2012000493A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Un método para sintetizar un compuesto derivado de piperazina disustituida con bencilo y ácido nicotínico, útiles para el tratamiento de condiciones neurológicas.
CL2012000493A 2009-08-24 2012-02-24 Procedimiento de preparacion de 2-alquilamino-3-piridin-n-bencilpiperazin cetonas. CL2012000493A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23647709P 2009-08-24 2009-08-24

Publications (1)

Publication Number Publication Date
CL2012000493A1 true CL2012000493A1 (es) 2012-09-28

Family

ID=43649584

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000493A CL2012000493A1 (es) 2009-08-24 2012-02-24 Procedimiento de preparacion de 2-alquilamino-3-piridin-n-bencilpiperazin cetonas.

Country Status (22)

Country Link
US (2) US9278933B2 (es)
EP (1) EP2470182B1 (es)
JP (1) JP5727482B2 (es)
KR (1) KR101701362B1 (es)
CN (2) CN105693601A (es)
AU (1) AU2010289802C1 (es)
BR (1) BR112012004161B1 (es)
CA (1) CA2772080C (es)
CL (1) CL2012000493A1 (es)
DK (1) DK2470182T3 (es)
ES (1) ES2475721T3 (es)
HR (1) HRP20140621T1 (es)
IL (1) IL218298A (es)
IN (1) IN2012DN02370A (es)
MX (1) MX2012002335A (es)
NZ (1) NZ598891A (es)
PL (1) PL2470182T3 (es)
PT (1) PT2470182E (es)
RU (1) RU2567390C2 (es)
SG (1) SG178867A1 (es)
SI (1) SI2470182T1 (es)
WO (1) WO2011028548A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5727482B2 (ja) * 2009-08-24 2015-06-03 ニューラルステム， インコーポレイテッド 神経刺激性ピペラジンの合成
CN109952291B (zh) * 2016-09-12 2022-09-23 纽若斯丹公司 与糖尿病相关的神经缺陷的改善
US20180104240A1 (en) * 2016-10-18 2018-04-19 Neuralstem, Inc. Amelioration of radiation-induced cognitive dysfunction
US10042957B2 (en) 2017-01-12 2018-08-07 Innovationdock, Inc. Devices and methods for implementing dynamic collaborative workflow systems
WO2018148733A1 (en) * 2017-02-13 2018-08-16 Neuralstem, Inc. Amelioration of certain deficiencies due to stroke
US12545657B2 (en) 2020-12-23 2026-02-10 Baylor College Of Medicine Small-molecule modulators of the orphan nuclear receptor TLX
BR112023025330A2 (pt) 2021-06-03 2024-02-27 Alto Neuroscience Inc Método de tratamento de pacientes deprimidos com cognição fraca e seleção de outros pacientes beneficiados com agente benzilpiperazina-aminopiridina
US12233059B2 (en) 2022-12-05 2025-02-25 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent
WO2024123695A1 (en) 2022-12-05 2024-06-13 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agent
US12208096B2 (en) 2022-12-05 2025-01-28 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU175075B (hu) * 1977-06-30 1980-05-28 Egyt Gyogyszervegyeszeti Gyar Sposob poluchenija piperazidov piridin-karbonovoj kisloty
JPS54122283A (en) * 1978-03-13 1979-09-21 Sumitomo Chem Co Ltd Novel quinazoline derivative and its preparation
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
DE60330323D1 (de) 2002-03-29 2010-01-14 Schering Corp Stereoselektive alkylierung von chirale 2-methyl-4-geschützte piperazinen
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
WO2004053071A2 (en) * 2002-12-09 2004-06-24 Judith Kelleher-Andersson Method for discovering neurogenic agents
ATE374610T1 (de) * 2003-09-09 2007-10-15 Hoffmann La Roche 1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
AU2005297848B2 (en) 2004-10-29 2011-03-17 Msd K.K. Novel aminopyridine derivatives having selective Aurora-A inhibitory effect
US7754724B2 (en) * 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
AR058554A1 (es) * 2005-12-20 2008-02-13 Novartis Ag Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5.
JP5727482B2 (ja) * 2009-08-24 2015-06-03 ニューラルステム， インコーポレイテッド 神経刺激性ピペラジンの合成

Also Published As

Publication number Publication date
MX2012002335A (es) 2012-07-04
IL218298A0 (en) 2012-04-30
CA2772080A1 (en) 2011-03-10
EP2470182B1 (en) 2014-06-04
WO2011028548A1 (en) 2011-03-10
US9481649B2 (en) 2016-11-01
CA2772080C (en) 2017-05-30
KR101701362B1 (ko) 2017-02-01
RU2567390C2 (ru) 2015-11-10
IL218298A (en) 2017-03-30
CN105693601A (zh) 2016-06-22
ES2475721T3 (es) 2014-07-11
EP2470182A4 (en) 2013-04-24
BR112012004161B1 (pt) 2020-04-07
BR112012004161A2 (pt) 2016-03-29
AU2010289802A1 (en) 2012-04-12
IN2012DN02370A (es) 2015-08-21
JP5727482B2 (ja) 2015-06-03
HRP20140621T1 (hr) 2014-11-21
KR20120054642A (ko) 2012-05-30
JP2013502462A (ja) 2013-01-24
CN102711764A (zh) 2012-10-03
PT2470182E (pt) 2014-07-24
US20160090358A1 (en) 2016-03-31
EP2470182A1 (en) 2012-07-04
RU2012111227A (ru) 2013-10-10
HK1172844A1 (en) 2013-05-03
SG178867A1 (en) 2012-04-27
PL2470182T3 (pl) 2015-05-29
AU2010289802C1 (en) 2015-04-16
US9278933B2 (en) 2016-03-08
DK2470182T3 (da) 2014-07-21
NZ598891A (en) 2014-05-30
AU2010289802B2 (en) 2014-10-02
SI2470182T1 (sl) 2014-10-30
US20130005974A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
JOP20210064B1 (ar) طريقة لانتاج ( z)-ألفا-فلورو-بيتا-أمينو-أكريل الدهيدات مستبدلة
MX2012005358A (es) Procedimiento para la preparacion de etexilato de dabigatran.
TN2011000673A1 (en) Bace inhibitors
ZA201004848B (en) Method for the production of disubstituted imidazolium salts
EA201170872A1 (ru) Ингибиторы протеинкиназы
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
UA110338C2 (xx) Хімічні сполуки
MY156274A (en) COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION
BRPI1008021A2 (pt) Método para fabricação de 2,6-dioxabiciclo-(3.3.0)-octano-4,8-diona
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
GEP20135933B (en) Compounds as bradykinin b1 antagonists
UA110626C2 (uk) Спосіб одержання пан-інгібіторів циклінзалежної кінази формули (i), а також проміжні продукти цього процесу одержання
TN2012000248A1 (en) Novel spiropiperidine compounds
UA104438C2 (uk) Спосіб одержання дабігатрану і його проміжних сполук
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
GEP20135960B (en) New method of synthesis of ivabradine and pharmaceutically acceptable acid-additive salts thereof
WO2010102154A3 (en) Biaryl oxyacetic acid compounds
MY156873A (en) Novel forms of a multicyclic compound
PH12016501704A1 (en) Method for producing 2-acyliminopyridine derivative
UA117524C2 (uk) Стимулятори рослин, їх застосування та спосіб стимуляції рослин
MX342311B (es) Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl).
CL2008003065A1 (es) Proceso para preparar un compuesto derivado de acido carbamoil-fosfonico o del acido carbamoil-fosfinico.
MX2010003056A (es) Polimorfos de valomaciclovir.